메뉴 건너뛰기




Volumn 8, Issue 3, 2008, Pages 481-490

Improving outcomes in patients with advanced renal cell carcinoma

Author keywords

Mammalian target of rapamycin; mTOR; Renal cell carcinoma; Survival; Targeted therapies; Vascular endothelial growth factor

Indexed keywords

ALPHA INTERFERON; AP 23573; BEVACIZUMAB; EVEROLIMUS; INTERFERON; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; MEDROXYPROGESTERONE; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

EID: 45249113906     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.3.481     Document Type: Review
Times cited : (6)

References (54)
  • 1
    • 14144252047 scopus 로고    scopus 로고
    • Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma
    • Mekhail TM, Abou-Jawde RM, Boumerhi G et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J. Clin. Oncol. 23 (4), 832-841 (2005).
    • (2005) J. Clin. Oncol , vol.23 , Issue.4 , pp. 832-841
    • Mekhail, T.M.1    Abou-Jawde, R.M.2    Boumerhi, G.3
  • 3
    • 0028928749 scopus 로고
    • Chemotherapy for advanced renal-cell carcinoma: 1983-1993
    • Yagoda A, Abi-Rached B, Pettylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin. Oncol. 22(1), 42-60 (1995).
    • (1995) Semin. Oncol , vol.22 , Issue.1 , pp. 42-60
    • Yagoda, A.1    Abi-Rached, B.2    Pettylak, D.3
  • 4
    • 4844231761 scopus 로고    scopus 로고
    • Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma
    • Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 101 (7), 1545-1551 (2004).
    • (2004) Cancer , vol.101 , Issue.7 , pp. 1545-1551
    • Nanus, D.M.1    Garino, A.2    Milowsky, M.I.3    Larkin, M.4    Dutcher, J.P.5
  • 5
    • 0033978220 scopus 로고    scopus 로고
    • Systemic therapy for renal cell carcinoma
    • Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma, J. Urol. 163(2), 408-417 (2000).
    • (2000) J. Urol , vol.163 , Issue.2 , pp. 408-417
    • Motzer, R.J.1    Russo, P.2
  • 6
  • 7
    • 0028929682 scopus 로고
    • Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy
    • Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13(3), 688-696 (1995).
    • (1995) J. Clin. Oncol , vol.13 , Issue.3 , pp. 688-696
    • Fyfe, G.1    Fisher, R.I.2    Rosenberg, S.A.3    Sznol, M.4    Parkinson, D.R.5    Louie, A.C.6
  • 8
    • 0034796962 scopus 로고    scopus 로고
    • The changing natural history of renal cell carcinoma
    • Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J. Urol. 166(5), 1611-1623 (2001).
    • (2001) J. Urol , vol.166 , Issue.5 , pp. 1611-1623
    • Pantuck, A.J.1    Zisman, A.2    Belldegrun, A.S.3
  • 9
    • 33846148701 scopus 로고    scopus 로고
    • Sorafenib in advanced clear-cell renal-cell carcinoma
    • Escudier B, Eisen T, Stadler W et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356(2), 125-134 (2007).
    • (2007) N. Engl. J. Med , vol.356 , Issue.2 , pp. 125-134
    • Escudier, B.1    Eisen, T.2    Stadler, W.3
  • 10
    • 33846181370 scopus 로고    scopus 로고
    • Sunitinib versus interferon α in metastatic renal-cell carcinoma
    • Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma. N. Engl. J. Med. 356(2), 115-124 (2007).
    • (2007) N. Engl. J. Med , vol.356 , Issue.2 , pp. 115-124
    • Motzer, R.J.1    Hutson, T.E.2    Tomczak, P.3
  • 11
    • 37349080670 scopus 로고    scopus 로고
    • Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind Phase III trial
    • Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet 370(9605), 2103-2111 (2007).
    • (2007) Lancet , vol.370 , Issue.9605 , pp. 2103-2111
    • Escudier, B.1    Pluzanska, A.2    Koralewski, P.3
  • 12
    • 34249779568 scopus 로고    scopus 로고
    • Temsirolimus, interferon α, or both for advanced renal-cell carcinoma
    • Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356(22), 2271-2281 (2007).
    • (2007) N. Engl. J. Med , vol.356 , Issue.22 , pp. 2271-2281
    • Hudes, G.1    Carducci, M.2    Tomczak, P.3
  • 13
    • 0032772880 scopus 로고    scopus 로고
    • Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma
    • Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17(8), 2530-2540 (1999).
    • (1999) J. Clin. Oncol , vol.17 , Issue.8 , pp. 2530-2540
    • Motzer, R.J.1    Mazumdar, M.2    Bacik, J.3    Berg, W.4    Amsterdam, A.5    Ferrara, J.6
  • 14
    • 0034966994 scopus 로고    scopus 로고
    • A postoperative prognostic nomogram for renal cell carcinoma
    • Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J. Urol. 166(l), 63-67. (2001).
    • (2001) J. Urol , vol.166 , Issue.L , pp. 63-67
    • Kattan, M.W.1    Reuter, V.2    Motzer, R.J.3    Katz, J.4    Russo, P.5
  • 15
    • 0036138580 scopus 로고    scopus 로고
    • Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma
    • Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin. Oncol. 20(1), 289-296 (2002).
    • (2002) J Clin. Oncol , vol.20 , Issue.1 , pp. 289-296
    • Motzer, R.J.1    Bacik, J.2    Murphy, B.A.3    Russo, P.4    Mazumdar, M.5
  • 16
    • 0036893892 scopus 로고    scopus 로고
    • An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: The SSIGN score
    • Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J. Urol. 168(6), 2395-2400 (2002).
    • (2002) J. Urol , vol.168 , Issue.6 , pp. 2395-2400
    • Frank, I.1    Blute, M.L.2    Cheville, J.C.3    Lohse, C.M.4    Weaver, A.L.5    Zincke, H.6
  • 17
    • 0036895290 scopus 로고    scopus 로고
    • Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma
    • Zisman A, Pantuck AJ, Wieder J et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J. Clin. Oncol. 20(23), 4559-4566 (2002).
    • (2002) J. Clin. Oncol , vol.20 , Issue.23 , pp. 4559-4566
    • Zisman, A.1    Pantuck, A.J.2    Wieder, J.3
  • 18
    • 34248149330 scopus 로고    scopus 로고
    • Multi-institutional validation of a new renal cancer-specific survival nomogram
    • Karakiewicz PI, Briganti A, Chun FK et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin. Oncol. 25(11), 1316-1322 (2007).
    • (2007) J Clin. Oncol , vol.25 , Issue.11 , pp. 1316-1322
    • Karakiewicz, P.I.1    Briganti, A.2    Chun, F.K.3
  • 19
    • 0042914703 scopus 로고    scopus 로고
    • Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer
    • Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 21(16), 3127-3132 (2003).
    • (2003) J. Clin. Oncol , vol.21 , Issue.16 , pp. 3127-3132
    • Yang, J.C.1    Sherry, R.M.2    Steinberg, S.M.3
  • 20
    • 16644401873 scopus 로고    scopus 로고
    • Randomized Phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
    • McDermott DF, Regan MM, Clark JI et al. Randomized Phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin. Oncol. 23(l), 133-141 (2005).
    • (2005) J Clin. Oncol , vol.23 , Issue.L , pp. 133-141
    • McDermott, D.F.1    Regan, M.M.2    Clark, J.I.3
  • 21
    • 0033847587 scopus 로고    scopus 로고
    • Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma
    • Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J. Sci. Am. 6(Suppl. 1), S55-S57 (2000).
    • (2000) Cancer J. Sci. Am , vol.6 , Issue.SUPPL. 1
    • Fisher, R.I.1    Rosenberg, S.A.2    Fyfe, G.3
  • 22
    • 2442737061 scopus 로고    scopus 로고
    • Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer
    • Pyrhönen S, Salminen E, Ruutu M et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J. Clin. Oncol. 17(9), 2859-2867 (1999).
    • (1999) J. Clin. Oncol , vol.17 , Issue.9 , pp. 2859-2867
    • Pyrhönen, S.1    Salminen, E.2    Ruutu, M.3
  • 23
    • 0033514050 scopus 로고    scopus 로고
    • Interferon-α and survival in metastatic renal carcinoma: Early results of a randomised controlled trial
    • Medical Research Council Renal Cancer Collaborators
    • Medical Research Council Renal Cancer Collaborators. Interferon-α and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 353(9146), 14-17 (1999).
    • (1999) Lancet , vol.353 , Issue.9146 , pp. 14-17
  • 24
    • 0035934596 scopus 로고    scopus 로고
    • Radical nephrectomy plus interferon-α-based immunotherapy compared with interferon α alone in metastatic renal-cell carcinoma: A randomised trial
    • Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-α-based immunotherapy compared with interferon α alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358(9286), 966-970 (2001).
    • (2001) Lancet , vol.358 , Issue.9286 , pp. 966-970
    • Mickisch, G.H.1    Garin, A.2    van Poppel, H.3    de Prijck, L.4    Sylvester, R.5
  • 25
    • 0035818877 scopus 로고    scopus 로고
    • Nephrectomy followed by interferon α-2b compared with interferon α-2b alone for metastatic renal-cell cancer
    • Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon α-2b compared with interferon α-2b alone for metastatic renal-cell cancer. N. Engl. J. Med. 345(23), 1655-1659 (2001).
    • (2001) N. Engl. J. Med , vol.345 , Issue.23 , pp. 1655-1659
    • Flanigan, R.C.1    Salmon, S.E.2    Blumenstein, B.A.3
  • 26
    • 36448930484 scopus 로고    scopus 로고
    • Medroxyprogesterone, interferon α-2a, interleukin 2 or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: Results of a randomized controlled trial
    • Negrier S, Perol D, Ravaud A et al. Medroxyprogesterone, interferon α-2a, interleukin 2 or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 110(11), 2468-2477 (2007).
    • (2007) Cancer , vol.110 , Issue.11 , pp. 2468-2477
    • Negrier, S.1    Perol, D.2    Ravaud, A.3
  • 27
    • 0036739439 scopus 로고    scopus 로고
    • Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: A report from the Groupe Francais d'Immunotherapie
    • Négrier S, Escudier B, Gomez F et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. Ann. Oncol. 13(9), 1460-1468 (2002).
    • (2002) Ann. Oncol , vol.13 , Issue.9 , pp. 1460-1468
    • Négrier, S.1    Escudier, B.2    Gomez, F.3
  • 28
    • 20344362911 scopus 로고    scopus 로고
    • Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours
    • Awada A, Hendlisz A, Gil T et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br. J. Cancer 92(10), 1855-1861 (2005).
    • (2005) Br. J. Cancer , vol.92 , Issue.10 , pp. 1855-1861
    • Awada, A.1    Hendlisz, A.2    Gil, T.3
  • 29
    • 33744984843 scopus 로고    scopus 로고
    • Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma
    • Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24(16), 2505-2512 (2006).
    • (2006) J. Clin. Oncol , vol.24 , Issue.16 , pp. 2505-2512
    • Ratain, M.J.1    Eisen, T.2    Stadler, W.M.3
  • 30
    • 34548315347 scopus 로고    scopus 로고
    • Final results of the randomized Phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis
    • Abstract 5023
    • Bukowski RM, Eisen T, Szczylik C et al. Final results of the randomized Phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J. Clin. Oncol. 25(Suppl. 18), (2007) (Abstract 5023).
    • (2007) J. Clin. Oncol , Issue.SUPPL. 18 , pp. 25
    • Bukowski, R.M.1    Eisen, T.2    Szczylik, C.3
  • 31
    • 34548263735 scopus 로고    scopus 로고
    • Phase II trial of sorafenib plus interferon α-2b as first- or second-line therapy in patients with metastatic renal cell cancer
    • Gollob JA, Rathmell WK, Richmond TM et al. Phase II trial of sorafenib plus interferon α-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J. Clin. Oncol. 25(22), 3288-3295 (2007).
    • (2007) J. Clin. Oncol , vol.25 , Issue.22 , pp. 3288-3295
    • Gollob, J.A.1    Rathmell, W.K.2    Richmond, T.M.3
  • 32
    • 34548229506 scopus 로고    scopus 로고
    • Sorafenib with interferon α-2b as first-line treatment of advanced renal carcinoma: A Phase II study of the Southwest Oncology Group
    • Ryan CW, Goldman BH, Lara PN Jr et al. Sorafenib with interferon α-2b as first-line treatment of advanced renal carcinoma: a Phase II study of the Southwest Oncology Group. J. Clin. Oncol. 25(22), 3296-3301 (2007).
    • (2007) J. Clin. Oncol , vol.25 , Issue.22 , pp. 3296-3301
    • Ryan, C.W.1    Goldman, B.H.2    Lara Jr, P.N.3
  • 33
    • 35548931472 scopus 로고    scopus 로고
    • Randomized Phase II trial of first line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results
    • Abstract 5025
    • Szczylik C, Demkow T, Staehler M et al. Randomized Phase II trial of first line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. Proc. Am. Soc. Clin. Oncol. 25, S18 (2007) (Abstract 5025).
    • (2007) Proc. Am. Soc. Clin. Oncol , vol.25
    • Szczylik, C.1    Demkow, T.2    Staehler, M.3
  • 34
    • 12244301581 scopus 로고    scopus 로고
    • In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship
    • Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9(1), 327-337 (2003).
    • (2003) Clin. Cancer Res , vol.9 , Issue.1 , pp. 327-337
    • Mendel, D.B.1    Laird, A.D.2    Xin, X.3
  • 35
    • 0038204144 scopus 로고    scopus 로고
    • SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
    • O'Farrell AM, Abrams TJ, Yuen HA et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101(9), 3597-3605 (2003).
    • (2003) Blood , vol.101 , Issue.9 , pp. 3597-3605
    • O'Farrell, A.M.1    Abrams, T.J.2    Yuen, H.A.3
  • 36
    • 33644833910 scopus 로고    scopus 로고
    • Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
    • Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24(1), 16-24 (2006).
    • (2006) J. Clin. Oncol , vol.24 , Issue.1 , pp. 16-24
    • Motzer, R.J.1    Michaelson, M.D.2    Redman, B.G.3
  • 37
    • 33744954585 scopus 로고    scopus 로고
    • Sunitinib in patients with metastatic renal cell carcinoma
    • Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295(21), 2516-2524 (2006).
    • (2006) JAMA , vol.295 , Issue.21 , pp. 2516-2524
    • Motzer, R.J.1    Rini, B.I.2    Bukowski, R.M.3
  • 38
    • 34548310217 scopus 로고    scopus 로고
    • Sunitinib versus interferon-α (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors
    • Abstract 5024
    • Motzer RJ. Sunitinib versus interferon-α (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors. J. Clin. Oncol. 24(Suppl. 18), (2007) (Abstract 5024).
    • (2007) J. Clin. Oncol , Issue.SUPPL. 18 , pp. 24
    • Motzer, R.J.1
  • 39
    • 0042343801 scopus 로고    scopus 로고
    • A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
    • Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349(5), 427-434 (2003).
    • (2003) N. Engl. J. Med , vol.349 , Issue.5 , pp. 427-434
    • Yang, J.C.1    Haworth, L.2    Sherry, R.M.3
  • 40
    • 45249099664 scopus 로고    scopus 로고
    • Torisel™, package insert. Wyeth Pharmaceuticals, Inc, PA, USA 2007
    • Torisel™, package insert. Wyeth Pharmaceuticals, Inc., PA, USA (2007).
  • 41
    • 0034644525 scopus 로고    scopus 로고
    • Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 103(2), 253-262 (2000).
    • Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 103(2), 253-262 (2000).
  • 42
    • 0345732640 scopus 로고    scopus 로고
    • mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E
    • Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol. Cell Biol. 24(1), 200-216 (2004).
    • (2004) Mol. Cell Biol , vol.24 , Issue.1 , pp. 200-216
    • Fingar, D.C.1    Richardson, C.J.2    Tee, A.R.3    Cheatham, L.4    Tsou, C.5    Blenis, J.6
  • 43
    • 33745242315 scopus 로고    scopus 로고
    • Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus
    • DelBufalo D, Ciuffreda L, Trisciuoglio D et al. Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res. 66(11), 5549-5554 (2006).
    • (2006) Cancer Res , vol.66 , Issue.11 , pp. 5549-5554
    • DelBufalo, D.1    Ciuffreda, L.2    Trisciuoglio, D.3
  • 45
    • 1542398693 scopus 로고    scopus 로고
    • Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell. carcinoma
    • Atkins MB, Hidalgo M, Stadler WM et al. Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell. carcinoma. J. Clin. Oncol. 22(5), 909-918 (2004).
    • (2004) J. Clin. Oncol , vol.22 , Issue.5 , pp. 909-918
    • Atkins, M.B.1    Hidalgo, M.2    Stadler, W.M.3
  • 46
    • 34547636060 scopus 로고    scopus 로고
    • Correlation of survival with tumor histology, age and prognostic-risk group for previously untreated patients with advanced renal cell carcinoma receiving temsirolimus or interferon alpha
    • Abstract 5033
    • Dutcher J, Szczylik C, Tannir N et al. Correlation of survival with tumor histology, age and prognostic-risk group for previously untreated patients with advanced renal cell carcinoma receiving temsirolimus or interferon alpha. J. Clin. Oncol. 25(Suppl. 18), (2007) (Abstract 5033).
    • (2007) J. Clin. Oncol , Issue.SUPPL. 18 , pp. 25
    • Dutcher, J.1    Szczylik, C.2    Tannir, N.3
  • 47
    • 37849001813 scopus 로고    scopus 로고
    • Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma
    • Choueiri TK, Plantade A, Elson P et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J. Clin. Oncol. 26(1), 127-131 (2008).
    • (2008) J. Clin. Oncol , vol.26 , Issue.1 , pp. 127-131
    • Choueiri, T.K.1    Plantade, A.2    Elson, P.3
  • 48
    • 45249107628 scopus 로고    scopus 로고
    • Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon-α (IFN) or the combination of IFN + TEMSR [poster]
    • Presented at:, Chicago, IL, USA, 1-5 June
    • Mallick RS, Parasuraman S, Hudes G et al. Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon-α (IFN) or the combination of IFN + TEMSR [poster]. Presented at: Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 1-5 June 2007.
    • (2007) Annual Meeting of the American Society of Clinical Oncology
    • Mallick, R.S.1    Parasuraman, S.2    Hudes, G.3
  • 49
    • 36849031075 scopus 로고    scopus 로고
    • A Phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies
    • Abstract 3512
    • Patnaik A, Ricart A, Cooper J et al. A Phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies. J. Clin. Oncol. 25(Suppl. 18), (2007) (Abstract 3512).
    • (2007) J. Clin. Oncol , Issue.SUPPL. 18 , pp. 25
    • Patnaik, A.1    Ricart, A.2    Cooper, J.3
  • 50
    • 36749098248 scopus 로고    scopus 로고
    • Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results
    • Abstract 5034
    • Merchan JR, Liu G, Fitch T et al. Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results. J. Clin. Oncol. 25(18S), (2007) (Abstract 5034).
    • (2007) J. Clin. Oncol , Issue.18 S , pp. 25
    • Merchan, J.R.1    Liu, G.2    Fitch, T.3
  • 51
    • 45249083767 scopus 로고    scopus 로고
    • Phase I study or erlotinib and CCI-779 (temsirolimus) for patients with recurrent malignant gliomas (MG) (NABTC 04-02)
    • Abstract 2057
    • Robins HI, Wen PY, Chang SM et al. Phase I study or erlotinib and CCI-779 (temsirolimus) for patients with recurrent malignant gliomas (MG) (NABTC 04-02) J. Clin. Oncol. 25(18S), Abstract 2057 (2007).
    • (2007) J. Clin. Oncol , Issue.18 S , pp. 25
    • Robins, H.I.1    Wen, P.Y.2    Chang, S.M.3
  • 52
    • 45249100572 scopus 로고    scopus 로고
    • Amato RJ, Misellati A, Khan M, Chiang S. A Phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC) [abstract]. J. Clin. Oncol. 18(24 Suppl.), (2006) (Abstract 4530).
    • Amato RJ, Misellati A, Khan M, Chiang S. A Phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC) [abstract]. J. Clin. Oncol. 18(24 Suppl.), (2006) (Abstract 4530).
  • 53
    • 35548977012 scopus 로고    scopus 로고
    • A Phase II trial of RAD001 in patients (pts) with metastatic renal cell carcinoma (MRCC)
    • Abstract 5107
    • Jac J, Giessinger S, Khan M, Willis J, Chiang S, Amato R. A Phase II trial of RAD001 in patients (pts) with metastatic renal cell carcinoma (MRCC). J. Clin. Oncol. 25(18S), (2007) (Abstract 5107).
    • (2007) J. Clin. Oncol , Issue.18 S , pp. 25
    • Jac, J.1    Giessinger, S.2    Khan, M.3    Willis, J.4    Chiang, S.5    Amato, R.6
  • 54
    • 37549061995 scopus 로고    scopus 로고
    • A Phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell carccinoma (mRCC) [abstract]
    • Abstract 5026
    • Amato RJ, Harris P, Dalton M et al. A Phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell carccinoma (mRCC) [abstract]. J. Clin. Oncol. 25(Suppl. 18), (2007) (Abstract 5026).
    • (2007) J. Clin. Oncol , Issue.SUPPL. 18 , pp. 25
    • Amato, R.J.1    Harris, P.2    Dalton, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.